Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Evaluation of hematologic profile may be needed for patients treated with oxcarbazepine

  • Jung, Gu Hyun (Department of Pediatrics, Inje University Sanggye Paik Hospital) ;
  • You, Su Jeong (Department of Pediatrics, Inje University Sanggye Paik Hospital)
  • Received : 2019.01.03
  • Accepted : 2019.04.10
  • Published : 2019.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The major side effects of treatment with oxcarbazepine (OXC) are skin rash and hyponatremia. Hematologic side effects are reported rarely. The aim of this study was to investigate the rate and types of the hematologic side effects of OXC. Methods: The medical records of 184 patients diagnosed with epilepsy or movement disorder and on OXC monotherapy, at the Department of Pediatrics of Inje University Sanggye Paik Hospital from July 2001 to July 2018, were retrospectively reviewed. Results: Of the 184 patients, 10 (5.4%) developed leukopenia in addition to pancytopenia and 2 (1.0%) developed pancytopenia. Leukopenia developed in 11 days to 14 years after OXC administration and was more frequent in males than in females (male vs. female, 9 vs. 1; Fisher exact test, P<0.05). Of the eight patients with leukopenia alone, 7 continued OXC treatment; 6 improved without intervention; 1 was lost to follow-up; and 1 received a reduced OXC dose, who improved after intervention. Pancytopenia developed within 2 months of initiation of OXC treatment. Both patients initially continued OXC. One improved within 1 month and continued treatment with OXC, but the other showed progression of the side effect, leading to the discontinuation of OXC and subsequent improvement within 1 month. There were no significant differences in the ages of the patients, OXC dose, and duration of OXC treatment between patients with and without these side effects of OXC (P>0.05, t-test). Conclusion: OXC-induced leukopenia is not rare and may result in pancytopenia. Patients being treated with OXC should be regularly monitored for abnormal complete blood count profiles.

Keywords

References

  1. Kalis MM, Huff NA. Oxcarbazepine, an antiepileptic agent. Clin Ther 2001;23:680-700. https://doi.org/10.1016/S0149-2918(01)80019-9
  2. Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989;3: 70-6. https://doi.org/10.1016/0920-1211(89)90070-3
  3. Dam M. Practical aspects of oxcarbazepine treatment. Epilepsia 1994; 35 Suppl 3:S23-5. https://doi.org/10.1111/j.1528-1157.1994.tb05943.x
  4. Dichter MA, Brodie MJ. New antiepileptic drugs. N Engl J Med 1996;3 34:1583-90. https://doi.org/10.1056/NEJM199606133342407
  5. Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999; 21:489-501. https://doi.org/10.2165/00002018-199921060-00005
  6. Hitiris N, Brodie MJ. Modern antiepileptic drugs: guidelines and beyond. Curr Opin Neurol 2006;19:175-80. https://doi.org/10.1097/00019052-200604000-00013
  7. Horga de la Parte JF, Horga A. Oxcarbazepine in the treatment of epilepsy. A review and update. Rev Neurol 2006;42:95-113. https://doi.org/10.33588/rn.4202.2005576
  8. Milia A, Pilia G, Mascia MG, Moller J, Cocco E, Marrosu MG. Oxcarbazepine-induced leukopenia. J Neuropsychiatry Clin Neurosci 2008; 20:502-3. https://doi.org/10.1176/jnp.2008.20.4.502
  9. Son YR, Son YR, Kim YS, Kim YS, Chu K, Chu K, et al. Oxcarbazepine induced leukopenia. J Korean Epilepsy Soc 2013;17:22-3.
  10. Calamaras MR, Stowe ZN, Newport DJ. Pancytopenia associated with the introduction of oxcarbazepine. J Clin Psychopharmacol 2007;27: 217-8. https://doi.org/10.1097/01.jcp.0000264971.92828.b2
  11. Serdaroglu G, Kurul S, Tutuncuoglu S, Dirik E, Sarioglu B. Oxcarbazepine in the treatment of childhood epilepsy. Pediatr Neurol 2003;28: 37-41. https://doi.org/10.1016/S0887-8994(02)00467-8
  12. Lloyd P, Flesch G, Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 1994;35 Suppl 3:S10-3. https://doi.org/10.1111/j.1528-1157.1994.tb05938.x
  13. Benes J, Parada A, Figueiredo AA, Alves PC, Freitas AP, Learmonth DA, et al. Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives. J Med Chem 1999;42:2582-7. https://doi.org/10.1021/jm980627g
  14. Balon R, Berchou R. Hematologic side effects of psychotropic drugs. Psychosomatics 1986;27:119-20,125-7. https://doi.org/10.1016/S0033-3182(86)72722-9
  15. Moss RA. Drug-induced immune thrombocytopenia. Am J Hematol 1980;9:439-46. https://doi.org/10.1002/ajh.2830090412
  16. Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol 2008;23 Suppl 1:27-41. https://doi.org/10.1002/hup.917
  17. Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Browne TR, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985;313:145-51. https://doi.org/10.1056/NEJM198507183130303
  18. Pisciotta AV. Drug-induced leukopenia and aplastic anemia. Clin Pharmacol Ther 1971;12:13-43. https://doi.org/10.1002/cpt197112113
  19. Kaufman DW, Kelly JP, Anderson T, Harmon DC, Shapiro S. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia 1997;38:1265-9. https://doi.org/10.1111/j.1528-1157.1997.tb00062.x
  20. Pennell PB, Ogaily MS, Macdonald RL. Aplastic anemia in a patient receiving felbamate for complex partial seizures. Neurology 1995;45 (3 Pt 1):456-60. https://doi.org/10.1212/WNL.45.3.456
  21. Franceschi M, Ciboddo G, Truci G, Borri A, Canal N. Fatal aplastic anemia in a patient treated with carbamazepine. Epilepsia 1988;29: 582-3. https://doi.org/10.1111/j.1528-1157.1988.tb03765.x

Cited by

  1. Why should we monitor for hematologic adverse drug reactions to oxcarbazepine? vol.62, pp.8, 2019, https://doi.org/10.3345/kjp.2019.00472
  2. Oxcarbazepine : Leucopenia and pancytopenia : 4 case reports vol.1772, pp.1, 2019, https://doi.org/10.1007/s40278-019-68387-4
  3. Trigeminal Neuralgia: Basic and Clinical Aspects vol.18, pp.2, 2019, https://doi.org/10.2174/1570159x17666191010094350
  4. The ‘collateral side’ of mood stabilizers: safety and evidence-based strategies for managing side effects vol.19, pp.11, 2019, https://doi.org/10.1080/14740338.2020.1820984
  5. Comparative assessment of health-related quality of life with and without anticonvulsant therapy in patients with childhood epilepsy with centrotemporal spikes vol.49, pp.8, 2019, https://doi.org/10.1177/03000605211039805